FDA authorized Aletta, a robotic venous blood collection device for supervised outpatient use, through the De Novo pathway.
The FDA has granted De Novo marketing authorization to Aletta, a standalone robotic device that performs venous blood collection from adults without hands-on operator intervention. The device is authorized for outpatient use under the oversight of a supervisor trained in phlebotomy; 1 phlebotomist may supervise as many as 3 devices concurrently.¹
“Blood draws are one of the most commonly performed medical procedures in the United States, yet patients may face delays due to a growing shortage of trained phlebotomists,” said Michelle Tarver, MD, PhD, director of the FDA’s Center for Devices and Radiological Health.¹ The authorization could provide outpatient practices and laboratories with another approach to blood collection, although its effects on access, workflow, and staffing have not yet been established in routine clinical use.
A trained phlebotomist initiates each Aletta session and must remain available to address problems. After the patient positions an arm, the patient or supervisor presses a button to begin. The device uses near-infrared imaging and Doppler ultrasonography to identify a suitable vein and distinguish it from arteries. If an appropriate vein cannot be identified, Aletta does not attempt venipuncture.¹
Once a vein is selected, the system applies a tourniquet, disinfects the skin, inserts the needle, changes collection tubes, disposes of the needle, and applies a bandage. Human oversight remains necessary: the supervisor confirms that tubes are collected in the correct order and verifies that each tube contains an adequate specimen.¹
According to the FDA, the authorization was supported by clinical data showing that Aletta’s successful blood-draw rate was comparable to or better than that of trained human phlebotomists when the device proceeded with a needle stick. The evaluated population included individuals with different health conditions and skin tones, as well as patients who reported difficult venous access. Device-related adverse events were described as uncommon and mild.¹
The agency’s announcement did not provide the study size, numerical success rates, comparator methods, confidence intervals, specific adverse-event types, or peer-reviewed trial citation. Consequently, the magnitude and precision of the reported performance difference cannot be independently assessed from the authorization announcement alone.
Aletta continuously applies disinfectant during ultrasonographic scanning and must be cleaned by a trained professional between patients. If excessive patient movement occurs, the needle detaches automatically and blood collection stops. Other onboard sensors can pause the procedure and alert the supervising phlebotomist when potentially unsafe conditions are detected.¹
The FDA used the De Novo pathway, which is intended for novel devices considered to pose low to moderate risk when no legally marketed predicate exists. The agency also established special controls addressing labeling, performance testing, and clinical testing. Compliance with these requirements, together with general device controls, is intended to provide reasonable assurance of safety and effectiveness.¹
Conventional outpatient blood collection depends on trained personnel to select a vein, perform venipuncture, manage collection tubes, and respond immediately to complications. Aletta automates many of these steps but does not eliminate the need for trained supervision or postcollection verification.
The authorization is limited to adults in outpatient settings. The announcement does not establish performance in children, hospitalized patients, emergency settings, or patients requiring specialized vascular access. Additional evidence will be needed to determine first-attempt success, specimen integrity, hemolysis rates, patient acceptability, throughput, cost, and performance after broad implementation. Postmarket experience will also be important for identifying uncommon device complications and clarifying which patients are most likely to benefit.
